BMRN - BioMarin Pharmaceutical Inc Stock Price, Fair Value and News

84.56USD-1.03 (-1.20%)Market Closed

Market Summary

USD84.56-1.03

Market Closed

-1.20%

BMRN Stock Price

View Fullscreen

BMRN RSI Chart

BMRN Valuation

Market Cap

16.1B

Price/Earnings (Trailing)

78.15

Price/Sales (Trailing)

6.5

EV/EBITDA

46.24

Price/Free Cashflow

88.31

BMRN Price/Sales (Trailing)

BMRN Profitability

Operating Margin

79.41%

EBT Margin

9.60%

Return on Equity

4.05%

Return on Assets

2.99%

Free Cashflow Yield

1.13%

BMRN Fundamentals

BMRN Revenue

Revenue (TTM)

2.5B

Rev. Growth (Yr)

8.79%

Rev. Growth (Qtr)

0.41%

BMRN Earnings

Earnings (TTM)

205.5M

Earnings Growth (Yr)

74.35%

Earnings Growth (Qtr)

335.15%

Breaking Down BMRN Revenue

Last 7 days

2.7%

Last 30 days

0.7%

Last 90 days

5.8%

Trailing 12 Months

-1.9%

How does BMRN drawdown profile look like?

BMRN Financial Health

Current Ratio

2.74

Debt/Equity

0.12

Debt/Cashflow

0.47

BMRN Investor Care

Shares Dilution (1Y)

1.16%

Diluted EPS (TTM)

1.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.5B	0	0	0
2023	2.2B	2.2B	2.3B	2.4B
2022	1.9B	1.9B	2.0B	2.1B
2021	1.8B	1.9B	1.8B	1.8B
2020	1.8B	1.8B	1.9B	1.9B
2019	1.5B	1.5B	1.6B	1.7B
2018	1.4B	1.4B	1.5B	1.5B
2017	1.2B	1.2B	1.3B	1.3B
2016	923.7M	973.7M	1.0B	1.1B
2015	801.0M	859.3M	891.7M	889.9M
2014	572.1M	627.1M	666.8M	749.6M
2013	512.0M	524.8M	533.5M	548.5M
2012	448.6M	461.9M	476.6M	500.7M
2011	400.8M	419.5M	435.1M	441.4M
2010	335.6M	344.8M	361.7M	376.3M
2009	0	305.9M	315.3M	324.7M
2008	0	0	0	296.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

CEO	Mr. Jean-Jacques Bienaime M.B.A., MBA
WEBSITE	biomarin.com
INDUSTRY	Biotechnology
EMPLOYEES	3082

BioMarin Pharmaceutical Inc Frequently Asked Questions

What is the ticker symbol for BioMarin Pharmaceutical Inc? What does BMRN stand for in stocks?

BMRN is the stock ticker symbol of BioMarin Pharmaceutical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioMarin Pharmaceutical Inc (BMRN)?

As of Thu Jul 25 2024, market cap of BioMarin Pharmaceutical Inc is 16.25 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BMRN stock?

You can check BMRN's fair value in chart for subscribers.

Is BioMarin Pharmaceutical Inc a good stock to buy?

The fair value guage provides a quick view whether BMRN is over valued or under valued. Whether BioMarin Pharmaceutical Inc is cheap or expensive depends on the assumptions which impact BioMarin Pharmaceutical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BMRN.

What is BioMarin Pharmaceutical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, BMRN's PE ratio (Price to Earnings) is 79.1 and Price to Sales (PS) ratio is 6.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BMRN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on BioMarin Pharmaceutical Inc's stock?

In the past 10 years, BioMarin Pharmaceutical Inc has provided 0.036 (multiply by 100 for percentage) rate of return.